Dr Enriqueta Felip speaks to ecancer about the IMpower010 study.
Dr Felip discusses the sites of relapse and subsequent therapy from a Phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC.
Initially, she explains the background and design of the study. She then discusses the key results from the study.
She explains that at this interim disease free survival analysis, relapse rate was higher in the BSC vs atezolizumab arm, but there was no clear difference in pattern of relapse between the arms among patients with relapse.
Dr Felip concludes by discussing how the results from this study can impact the future treatment of NSCLC.
Read more about this study here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.